Related Experiment Video
Updated: Aug 30, 2025

Murine Echocardiography of Left Atrium, Aorta, and Pulmonary Artery
Published on: February 20, 2017
Left ventricular size and function in patients with systemic lupus erythematosus associate with lupus anticoagulant:
Katrine A Myhr1, Amanda H Zinglersen2, Marie-Louise F Hermansen2
1Department of Cardiology, Rigshospitalet, Inge Lehmanns Vej 7, 2100, Copenhagen, Denmark.
Insights
Lupus anticoagulant (LAC) is linked to worsening diastolic function and progressive left ventricular enlargement in patients with systemic lupus erythematosus (SLE). This suggests LAC may predict cardiac dysfunction in SLE patients over time.
Area of Science:
- Cardiology
- Rheumatology
- Immunology
Background:
- Systemic lupus erythematosus (SLE) is a chronic autoimmune disease associated with a higher risk of cardiac dysfunction.
- The underlying mechanisms of cardiac involvement in SLE are not fully understood, necessitating the identification of prognostic markers.
Purpose of the Study:
- To identify characteristics of SLE associated with cardiac size and function over a five-year follow-up period.
- To investigate potential biomarkers for cardiac dysfunction in SLE patients.
Main Methods:
- A cohort of 108 SLE patients underwent baseline and 5-year follow-up echocardiography and blood sampling.
- Multivariate regression analyses were performed to assess associations between SLE-related variables (including lupus anticoagulant [LAC]) and echocardiographic parameters, adjusting for traditional risk factors.
Main Results:
- Diastolic function declined in SLE patients during follow-up, with significant changes in E/A ratio and tricuspid regurgitation peak velocity.
- Left ventricular end-diastolic volume index increased, indicating progressive cardiac dilation.
- Lupus anticoagulant (LAC) was significantly associated with impaired diastolic function and left ventricular dilation over the 5-year period.
Conclusions:
- The presence of LAC is associated with diastolic dysfunction and progressive left ventricular dilation in SLE patients.
- Lupus anticoagulant (LAC) may serve as a predictor of cardiac dysfunction in individuals with systemic lupus erythematosus.
- Further research is needed to elucidate the clinical significance of these findings regarding microvascular circulation and cardiac outcomes.
Background:
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with increased risk of cardiac dysfunction. The pathophysiological mechanisms are poorly understood, and prognostic markers are warranted.
Purpose:
We aimed to identify SLE-characteristics associated with measures of cardiac size and function during a five-year follow-up.
Methods:
We included 108 patients with SLE: 90% females, mean age 46 ± 13 years, median disease duration 14 (range 7-21) years. We performed blood sampling for potential biomarkers as well as a standard echocardiography at baseline and at a 5-year follow-up. To investigate associations with baseline and prospective 5-year changes in echocardiographic parameters, we performed multivariate regression analyses of SLE-related baseline variables (clinical disease activity, lupus nephritis, chronic kidney disease, anti-cardiolipin and/or anti-beta-2 glycoprotein I antibodies, and lupus anticoagulant (LAC)) and adjusted for traditional risk factors.
Results:
During follow-up, diastolic function regressed in two out of five echocardiographic measures (E/A ratio 1.4 ± 0.5 vs. 1.3 ± 0.5, p = 0.002; tricuspid regurgitation peak velocity 2.0 ± 0.6 vs. 2.2 ± 0.4 mmHg, p < 0.001). Left ventricular (LV) end-diastolic volume index increased (43.7 ± 13.9 vs. 52.5 ± 15.7 mL/m2, p < 0.001). Left and right ventricular systolic function remained stationary. LAC was associated with inferior diastolic function: lower E/A ratio (p = 0.04) and higher E/e' ratio at baseline (p = 0.04) and increased left ventricular atrial volume index during follow-up (p = 0.01). LAC was further associated with LV dilatation during follow-up (p = 0.01).
Conclusion:
Presence of LAC was associated with measures of diastolic function as well as progressive LV dilatation during the 5-year follow-up. Thus, LAC might be a predictor of cardiac dysfunction in SLE patients. LAC is known to have implications for the microvascular circulation, but the clinical significance of the present findings is yet to be elucidated.
More Related Videos
Related Concept Videos
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Imaging Studies for Cardiovascular System II:Types of Echocardiography
Types of Echocardiography
Transthoracic Echocardiography (TTE)
TTE is the most common type of echocardiogram which involves placing a transducer on the patient's chest, emitting sound waves to create heart images. TTE is invaluable for evaluating the heart's size, structure, and motion, making it particularly useful for...
Imaging Studies for Cardiovascular System I:Echocardiography
Indications: Echocardiography is utilized to diagnose heart failure, valve disorders, and myocardial infarction. It also assesses cardiac structures' size, shape, and motion,...
Aortic Regurgitation II: Clinical Features and Diagnostic Tests

